Global Irritable Bowel Syndrome Drugs Market Definition
Irritable bowel syndrome (IBS) is the most prevalent gastrointestinal disease in the general population that is known to affect the large intestine. It is a chronic condition characterized by symptoms and signs which include constipation or diarrhea, bloating, gas, abdominal pain, cramping, and others. Technically, what causes irritable bowel syndrome is still exactly unknown, but it has been found that several other factors, which include contractions of muscles in the intestine, early life stress, or changes in gut microbes, play an important role for causing IBS disease. IBS treatment focuses on symptom relief to help people live a symptom-free life as possible. Mild symptoms can frequently be reduced by stress management techniques, as well as dietary and lifestyle changes. Doctors may prescribe a particular medication or drugs, known as irritable bowel syndrome drugs, if the symptoms don't go away, worsen, or become chronic. At times, a blood test for IBS detection is also performed to know the severity of the disease. Doctors also suggest the patients to avoid certain foods and at times also suggest a strict diet to cure IBS disease permanently. Some of the common medications used frequently for irritable bowel syndrome treatment include antibiotics such as rifaximin, therapeutic agents such as eluxadoline, chloride channel activators such as lubiprostone, and guanylate cyclase-C agonists such as linaclotide among others. Besides this, laxatives, tricyclic antidepressants, anti-diarrheal pharmaceuticals, anticholinergic agents, painkillers, and fiber supplements are also used for the treatment of IBS disease.
Global Irritable Bowel Syndrome Drugs Market: Key Insights
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~14% |
|
Base Year Market Size (2022) |
~ USD 2 Billion |
|
Forecast Year Market Size (2035) |
~ USD 5 Billion |
|
Regional Scope |
|
Global Irritable Bowel Syndrome Drugs Market Size, Forecast, and Trend Highlights Over 2023 - 2035
The global irritable bowel syndrome drugs market is estimated to garner a revenue of USD 5 Billion by the end of 2035 by growing at a CAGR of ~14% over the forecast period, i.e., 2023 – 2035. Further, the market generated a revenue of USD 2 Billion in the year 2022. The growth of the market can be attributed to the increasing number of elderly people who are prone to different types of gastrointestinal diseases. Further, the growing prevalence of gastrointestinal diseases amongst other population group, an increase in the consumption of unhealthy foods, and rising stress levels among people across the globe are also expected to add to the market growth. The estimated prevalence of irritable bowel syndrome in the United States is between 11% and 14% and this share is predicted to increase further in the years to come.
Get more information on this report:Download Sample PDF
In addition to these, factors that are believed to fuel the market growth of irritable bowel syndrome drugs include the rise in over-the-counter drug availability, soaring investments, and collaboration between major key players to discover effective treatments for IBS. For instance, on June 9, 2022, the biopharmaceutical company Ferring B.V. announced a strategic partnership with the innovation-focused global biopharma company I-MAB Biopharma Co., Ltd. to advance the development of olamkicept, a selective interleukin-6 (IL-6) trans-signaling inhibitor for inflammatory bowel disease (IBD) and associated inflammatory conditions. Additionally, the growing number of awareness campaigns on the management of irritable bowel syndrome is predicted to present the potential for market expansion over the projected period.
Global Irritable Bowel Syndrome Drugs Market: Growth Drivers and Challenges
Growth Drivers
-
Growing Prevalence of Diarrhea in Children – On account of the increasing prevalence of gastrointestinal disorders in children, including diarrhea, constipation, and bowel incontinence, the market is expected to expand more in the upcoming years. Diarrhea is listed as the second most typical cause of death in children under the age of five by the World Health Organization. Each year, diarrhea kills about 500 000 children under the age of five. Around 2 billion children worldwide have diarrheal sickness every year.
-
Rising Geriatric Population – Elderly population is more prone to bowel incontinence and the rising number of elderly populations across the globe is estimated to drive market growth. The percentage of individuals over 60 in the world will nearly double from 12 to 22% between 2015 and 2050. In 2020, there were more people over the age of 60 than children under five and by 2050, it is predicted that 80% of the world's old people will live in low- and middle-income countries.
-
Increasing Health Spending – According to the most recent expenditure data, global health spending has grown over the past 20 years, doubling in real terms to reach USD 8.5 trillion in 2019 and 9.8% of GDP, up from 8.5 percent in 2000. It is predicted that this boom would continue over the forecast period.
-
Growing Incidences of Spinal Cord Injuries – It is expected that patients with chronic illnesses and disabilities, including spinal cord injuries, experience bowel incontinence more severely, which is anticipated to drive the market growth. It was discovered that between 300,000 and 500,000 people worldwide experience spinal cord injuries every year.
-
Rising Cases of Hemorrhoids – Hemorrhoids can also be referred to as piles. Inflamed veins in the lower rectum and anus are hemorrhoids. Bowel incontinence can result from this swelling, thereby raising the need for hemorrhoids drugs, which is anticipated to drive the market growth. At least 50% of Americans over the age of 50 who have hemorrhoids experience obvious symptoms.
Challenges
-
Side effects of IBS drugs - The increasing concern amongst individuals for the side effects associated with the consumption of IBS drugs is one of the major factors predicted to slow down the market growth. For instance, pancreatitis, a serious and more common pancreatic inflammation, can arise from the dual mu-opioid nicotinic receptor eluxadoline, which is employed to address digestive problems with incontinence in some people.
-
Low awareness among people in low and middle-income countries for these drugs
-
Lack of medical reimbursement policies for treatment of IBS
The global irritable bowel syndrome drugs market is segmented and analyzed for demand and supply by type into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and mixed IBS (IBS-M). Out of these, the IBS with diarrhea (IBS-D) segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing prevalence of diarrhea among all age groups and the rising adoption of unhealthy lifestyles including the consumption of fast food and alcohol. For instance, diarrheal illnesses are believed to be responsible for 300 annual pediatric fatalities and 167,000 hospitalizations in the US.
Global Irritable Bowel Syndrome Drugs Market Regional Synopsis
The North American irritable bowel syndrome drugs market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed to the increasing frequency of fecal incontinence and the availability of efficient treatment options in the region. For instance, 50 to 70 patients out of every 100 nursing home residents and 18 to 33 patients out of every 100 hospitalized patients, respectively, suffer from fecal incontinence. Fecal incontinence affects 7 to 15 persons out of every 100 who are not patients or residents of nursing homes or hospitals. In addition, the region's supportive health policies and expanding healthcare industry are anticipated to boost the market expansion during the course of the anticipated period.
Market Segmentation
Our in-depth analysis of the global irritable bowel syndrome drugs market includes the following segments:
|
By Type |
|
|
By Product |
|
|
By End User |
|
Top Featured Companies Dominating the Global Irritable Bowel Syndrome Drugs Market
-
Abbott Services
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Ardelyx, Inc.
- Astellas Pharma Inc.
- AstraZeneca
- GlaxoSmithKline Plc
- Johnson & Johnson Services, Inc.
- Novartis AG
- Ironwood Pharmaceuticals, Inc.
- Synergy Pharma Consultancy Private Limited
- Synthetic Biologics, Inc
